What does venetoclax (venetoclax) do? What is the efficacy and what diseases is it suitable for?

Venetoclax (Venetoclax, also known as Venetoclax) is an innovative targeted therapy drug. Its mechanism of action is to inhibit the specific protein BCL-2 (B-cell lymphoma-2). BCL-2 is actually an anti-apoptotic protein. Under normal circumstances, it acts like a cell death switch and can prevent cells from undergoing programmed death, that is, apoptosis. However, in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML), cancerous blood cells often overexpress BCL-2, making them resistant to traditional chemotherapy drugs. Venetoclax reactivates the cell's death switch by directly binding to BCL-2, thereby causing cancer cells to undergo programmed death.

So, how effective is venetoclax? For adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), venetoclax can significantly reduce the number of cancer cells, prolong survival and improve quality of life. What’s more worth mentioning is that venetoclax can also be used in combination with other drugs, such as rituximab, to further improve the therapeutic effect. In clinical trials for CLL patients, the venetoclax combination treatment regimen demonstrated a high complete response rate and progression-free survival, which undoubtedly brings new hope to patients.

In addition to CLL and SLL, what other diseases is venetoclax suitable for? Venetoclax has also shown good efficacy in newly diagnosed adult acute myeloid leukemia (AML) patients who are not suitable for intensive induction chemotherapy due to comorbidities or who are aged 75 years and above. It can be used in combination with hypomethylating drugs (such as azacitidine or decitabine) or low-dose cytarabine (LDAC) to significantly improve patients' treatment response rate and extend survival. This combination therapy provides a new treatment option for elderly AML patients, especially those patients whose traditional chemotherapy regimens are ineffective or intolerable, and have seen a new dawn.

Of course, as a new type of targeted therapy, venetoclax has remarkable efficacy, but patients need to pay attention to its possible side effects when using it, such as neutropenia, increased risk of infection, and tumor lysis syndrome. Therefore, close monitoring and management must be carried out under the guidance of a doctor.

In general, venetoclax, with its targeted inhibition ofBCL-2 protein, has shown excellent efficacy and safety in the treatment of various hematological tumors, providing patients with more effective and personalized treatment options.

References:

https://www.drugs.com/venclexta.html